Teva receives FDA approval to market Eisai's Alzheimer's treatment Aricept Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Eisai's Alzheimer's treatment Aricept® (Donepezil Hydrochloride) Tablets, 5 mg and 10 mg. Shipment of this product has commenced.

Annual sales of the product, including brand and generic sales, were approximately $2.3 billion in the United States, based on IMS sales data.